Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
| العنوان: | Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade |
|---|---|
| المؤلفون: | Valerio Nardone, Rocco Giannicola, Giovanna Bianco, Diana Giannarelli, Paolo Tini, Pierpaolo Pastina, Antonia Consuelo Falzea, Sebastiano Macheda, Michele Caraglia, Amalia Luce, Silvia Zappavigna, Luciano Mutti, Luigi Pirtoli, Antonio Giordano, Pierpaolo Correale |
| المساهمون: | Nardone, V., Giannicola, R., Bianco, G., Giannarelli, D., Tini, P., Pastina, P., Falzea, A. C., Macheda, S., Caraglia, M., Luce, A., Zappavigna, S., Mutti, L., Pirtoli, L., Giordano, A., Correale, P. |
| المصدر: | Frontiers in Oncology Frontiers in Oncology, Vol 11 (2021) |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, medicine.medical_specialty, Durvalumab, Salvage therapy, Pembrolizumab, Gastroenterology, Procalcitonin, Avelumab, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Internal medicine, prognostic factors of response, medicine, cell death receptor, Lung cancer, programmed cell death ligand-1, RC254-282, Original Research, business.industry, bacterial infection, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, inflammatory markers, inflammatory marker, real-world salvage therapy, bacterial infections, immune-check point blockade, procalcitonin, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Nivolumab, business, medicine.drug |
| الوصف: | Peripheral-immune-checkpoint blockade (P-ICB) with mAbs to PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, durvalumab, avelumab) alone or combination with chemotherapy represents a novel active treatment for mNSCLC patients. However, this therapy can be associated to immune-related adverse events (irAEs) and high cost. Therefore, finding reliable biomarkers of response and irAEs is strongly encouraged to accurately select patients who may potentially benefit from the immuno-oncological treatment. This is a retrospective multi-institutional analysis performed on ninety-five mNSCLC patients who received real-world salvage therapy with nivolumab or atezolizumab between December 2015 and April 2020. The outcome of these patients in term of PFS and OS was evaluated in comparison with different serum levels of C-reactive protein (CRP), Erythrocyte Sedimention Rate (ESR) and Procalcitonin (PCT) by performing Kaplan–Meier and Log-rank test and multivariate analysis. We found that high baseline levels of CRP, ESR, and PCT were strongly predictive of poor outcome (P vs. those with just one marker over the cut off vs. those with both markers over the cut off: 40 ± 59 vs. 15.5 ± 5.5 vs. 5.5 ± 1.6 months, respectively; P |
| تدمد: | 2234-943X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cbc2d28bc8b055476a3a290898f44b4Test https://pubmed.ncbi.nlm.nih.gov/34195086Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2cbc2d28bc8b055476a3a290898f44b4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2234943X |
|---|